Toronto,, January 30, 2025 / Prnewswire /-Kinectrics and Isotopia have announced a revolutionary agreement under which the Kinectrics will provide isotopia a reliable supply of Gadolinium-160 (GD-160). This critical isotope will allow the production of isotopia of terbium-161 (TB-161), a medical isotope showing a great promise and superiority for use in radiotherapies, including therapies targeting prostate tumors and neuroendocrine.
This partnership represents a significant front step in the fight against access limited to GD-160, an obstacle which has long limited the advancement of treatments based on TB-161 in clinical trials. The Kinectrics provide proven expertise in the enrichment of isotopes to YTTTERBIUM-176 (YB-176) and now takes advantage of this technology to advance GD-160. Isotopia systematically produced high quality quantities at the Lu-177 commercial scale and has produced in the past two years on a weekly basis for its own clinical trial. With access to secure GD-160, this agreement should accelerate the development of Radiotherapeutics based on TB-161, bringing them closer to one more commercial availability.
David HarrisPresident and chief executive officer of Kinectricsexpressed his enthusiasm about the new agreement: “We are extremely happy to associate ourselves with isotopia in the supply of the critical isotope Gadolinium-160 to support their production of terbium-161. After years of research and development as well as Significant investments, Kinectrics is proud to produce highly enriched stable isotopes for the radiopharmaceutical industry.
Doctor Eli ShalomCEO of isotopia, If this had said about this long-term partnership: “The Terbium-161 has long been considered a promising radioactive isotope for targeted cancer therapy, as it has two different mechanisms for the destruction of cancer cells.
The TB-161 offers a potential advantage on LU-177 due to its core electrons emissions, which are very effective in targeting micro-metastases by causing double strand DNA ruptures. This mechanism can provide precise therapeutic advantages while reducing side effects compared to isotopes emitting alpha.
We are delighted with this partnership with Kinectrics, because it will allow isotopia to keep its promise to bring TB-161 to the market and allow us to advance our own drug products marked at TB-161.
Radiotherapeutics draw increasing attention to the medical community because of their ability to provide highly targeted treatment to cancer cells while minimizing collateral damage to surrounding healthy tissues.
About kinectrics
Kinectrics is a category leader in the provision of life cycle management services to the electricity industry. Known of customers around the world, our expertise in engineering, test, inspection and certification is supported by our independent laboratory and our test facilities, a diverse fleet of field inspection equipment and a award -winning team of more than 1,300 engineers and technical experts. From the first design and type tests to the operational deployment and maintenance services, the Kinectrics collaborate closely with customers to ensure that utility assets perform safe performance, reliably and efficiently throughout their cycle of life. Kinectrics is a founding member of the Nuclear Innovation Institute (NII) and the Canadian Nuclear Isotopes Council (CNIC).
About isotopia
Isotopia molecular imaging ltd. is a leader in the LU-177 and TB-161 offer, with a global manufacturing imprint Israel,, EuropeAnd The United States. His development team includes nuclear pharmacists, radiochimists, nuclear engineers and physicists. Combined with its nuclear pharmacy, Cyclotron Facility, 177Read / 161 TB production sites and the sterile manufacturing plant, isotopia, provides a well-established platform for manufacturing and industry collaborations. Isotopia collaborations with scientific and medical communities allow it to develop and experience more with new markers for imaging applications and molecular therapy.
Contact:
eshalom@isotopia-global.com
Isotopia source; Kinectrics
